FDA
-
-
-
-
-
-
-
60 Degrees Pharmaceuticals enrolls first patient in tafenoquine babesiosis trial
-
-
-
-
-
-
-
60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract
-
-
-
-
-
-
-
60 Degrees Pharmaceuticals partners with Runway Health for malaria drug
-
-
-
-
-
-
-
60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
-
-
-
-
-
-
-
60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study
-
-
-
-
-
-
-
60 Degrees Pharmaceuticals closes $5 million public offering
-
-
-
-
-
-
-
60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025
-
325,297 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

